Evidence map›Paper›PMID 40806544›Full record

ArticleInternational journal of molecular sciences2025

Prognostic Relevance of Clinical and Tumor Mutational Profile in High-Grade Serous Ovarian Cancer.

Javier Martín-Vallejo, Juan Ramón Berenguer-Marí, Raquel Bosch-Romeu, Julia Sierra-Roca, Irene Tadeo-Cervera, Juan Pardo, Antonio Falcó, Patricia Molina-Bellido, Juan Bautista Laforga, Pedro Antonio Clemente-Pérez and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Javier Martín-VallejoDepartment of Obstetrics and Gynecology, Hospital de Denia, 03700 Alicante, Spain.ORCID 0000-0003-2272-9428
Juan Ramón Berenguer-MaríDepartment of Medical Oncology, Hospital de Denia, 03700 Alicante, Spain.ORCID 0009-0004-5288-1791
Raquel Bosch-RomeuESI International Chair@CEU-UCH, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Alfara del Patriarca, Spain.ORCID 0000-0001-9126-3241
Julia Sierra-RocaDepartment of Obstetrics and Gynecology, La Ribera Salud, 46015 Sueca, Spain.
Irene Tadeo-CerveraECMOR Chair@CEU-UCH, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Alfara del Patriarca, Spain.ORCID 0000-0003-3690-5007
Juan PardoESI International Chair@CEU-UCH, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Alfara del Patriarca, Spain.ORCID 0000-0003-4184-9855
Antonio FalcóESI International Chair@CEU-UCH, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Alfara del Patriarca, Spain.ORCID 0000-0001-6225-0935
Patricia Molina-BellidoDepartment of Obstetrics and Gynecology, Hospital de Denia, 03700 Alicante, Spain.
Juan Bautista LaforgaDepartment of Pathology, Hospital de Denia, 03700 Alicante, Spain.
Pedro Antonio Clemente-PérezDepartment of Obstetrics and Gynecology, Hospital de Denia, 03700 Alicante, Spain.
Juan Manuel Gasent-BlesaDepartment of Medical Oncology, Hospital de Denia, 03700 Alicante, Spain.
Joan ClimentESI International Chair@CEU-UCH, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Alfara del Patriarca, Spain.ORCID 0000-0002-8927-6614

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of cases. This study investigates genetic mutations and their associations with overall survival (OS), complete cytoreduction (R0), and platinum response in patients undergoing either primary debulking surgery followed by adjuvant chemotherapy (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (NACT). Genetic analysis was performed on 43 primary HGSOC tumor samples using targeted massive parallel sequencing via next-generation sequencing (NGS). Clinical and molecular data were evaluated collectively and through subgroup comparisons between PDS and NACT cohorts. All analyzed samples harbored genetic alterations. Univariate survival analysis revealed that the total number of mutations (

Indexed as

Cystadenocarcinoma, SerousMutationOvarian NeoplasmsAdultAgedBiomarkers, TumorChemotherapy, AdjuvantCytoreduction Surgical ProceduresFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedNeoplasm GradingPrognosisReceptor, ErbB-4Biomarkers, TumorReceptor, ErbB-4ERBB4 mutationsHGSOCNGS

Identifiers

PMID40806544
PMCPMC12347516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.